Cardior Pharmaceuticals is a Germany-based company developing therapies that target RNA as a way to prevent, repair and reverse cardiovascular disease, the most common cause of death worldwide. The deal includes Cardior’s lead compound, CDR132l, which is in phase 2 clinical development and designed to stop and partially reverse heart damage, according to a March 25 news release.
Novo Nordisk said it plans to start a second phase 2 trial to investigate the compound in chronic heart failure patients who have problems with their heart muscle.
The acquisition comes several weeks after the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
